Advances in the Treatment of Metastatic HER2-Positive Breast Cancer
Sunil Verma, MD, MSEd, FRCPC, University of Toronto, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses advances in the treatment of patients with metastatic HER2-positive breast cancer.
Clinical Pearls
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses advances in the treatment of patients with metastatic HER2-positive breast cancer.
- In 1998, OS in this population was 20 months with chemotherapy alone versus 25 months with chemotherapy plus trastuzumab
- The CLEOPATRA study suggested that with pertuzumab, trastuzumab, chemotherapy, and other lines of anti-HER2 therapy, survival exceeds 45 months, though many patients did not receiveT-DM1
- Now, with first-line pertuzumab, second-line T-DM1, and third-/fourth-line subsequent anti-HER2 therapy, OS exceeds 5 years
- Challenges remain regarding the treatment of patients at risk of brain metastases
Recent Videos
Related Content
T-DXd Maintains QOL, Delays Pain Deterioration in HR+/HER2-Low/Ultralow MBC
September 15th 2024Article
Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.
Read More
